Autoimmune gastritis: Histology phenotype and OLGA staging

M. Rugge, M. Fassan, M. Pizzi, V. Zorzetto, G. Maddalo, S. Realdon, M. De Bernard, C. Betterle, R. Cappellesso, G. Pennelli, M. De Boni, F. Farinati

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background Among Western populations, the declining incidence of Helicobacter pylori infection coincides with a growing clinical impact of autoimmune gastritis. Aims To describe the histological phenotype of autoimmune gastritis, also to test the prognostic impact of OLGA staging in the autoimmune setting. Methods A single-institutional series (spanning the years 2003-2011) of 562 consecutive patients (M:F ratio: 1:3.7; mean age = 57.6 ± 14.4 years) with serologically confirmed autoimmune gastritis underwent histology review and OLGA staging. Results Helicobacter pylori infection was ascertained histologically in 44/562 cases (7.8%). Forty six biopsy sets (8.2%) featured OLGA stages III-IV; they included all four cases of incidental epithelial neoplasia (three intraepithelial and one invasive; three of these four cases had concomitant H. pylori infection). There were 230 (40.9%) and 139 (24.7%) cases, respectively, of linear and micro-nodular enterochromaffin-like cell hyperplasia; 19 (3.4%) type I carcinoids were detected. The series included 116 patients who underwent repeated endoscopy/biopsy sampling (mean time elapsing between the two procedures = 54 months; range 24-108). Paired histology showed a significant (P = 0.009) trend towards a stage progression [the stage increased in 25/116 cases (22%); it remained unchanged in 87/116 cases (75%)]. Conclusions In autoimmune gastritis, the cancer risk is restricted to high-risk gastritis stages (III-IV), and is associated mainly with concomitant H. pylori infection. OLGA staging consistently depicts the time-dependent organic progression of the autoimmune disease and provides key information for secondary gastric cancer prevention strategies.

Original languageEnglish
Pages (from-to)1460-1466
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume35
Issue number12
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Gastritis
Helicobacter Infections
Histology
Helicobacter pylori
Phenotype
Enterochromaffin-like Cells
Biopsy
Carcinoid Tumor
Endoscopy
Autoimmune Diseases
Stomach Neoplasms
Hyperplasia
Neoplasms
Incidence
Population

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Rugge, M., Fassan, M., Pizzi, M., Zorzetto, V., Maddalo, G., Realdon, S., ... Farinati, F. (2012). Autoimmune gastritis: Histology phenotype and OLGA staging. Alimentary Pharmacology and Therapeutics, 35(12), 1460-1466. https://doi.org/10.1111/j.1365-2036.2012.05101.x

Autoimmune gastritis : Histology phenotype and OLGA staging. / Rugge, M.; Fassan, M.; Pizzi, M.; Zorzetto, V.; Maddalo, G.; Realdon, S.; De Bernard, M.; Betterle, C.; Cappellesso, R.; Pennelli, G.; De Boni, M.; Farinati, F.

In: Alimentary Pharmacology and Therapeutics, Vol. 35, No. 12, 06.2012, p. 1460-1466.

Research output: Contribution to journalArticle

Rugge, M, Fassan, M, Pizzi, M, Zorzetto, V, Maddalo, G, Realdon, S, De Bernard, M, Betterle, C, Cappellesso, R, Pennelli, G, De Boni, M & Farinati, F 2012, 'Autoimmune gastritis: Histology phenotype and OLGA staging', Alimentary Pharmacology and Therapeutics, vol. 35, no. 12, pp. 1460-1466. https://doi.org/10.1111/j.1365-2036.2012.05101.x
Rugge, M. ; Fassan, M. ; Pizzi, M. ; Zorzetto, V. ; Maddalo, G. ; Realdon, S. ; De Bernard, M. ; Betterle, C. ; Cappellesso, R. ; Pennelli, G. ; De Boni, M. ; Farinati, F. / Autoimmune gastritis : Histology phenotype and OLGA staging. In: Alimentary Pharmacology and Therapeutics. 2012 ; Vol. 35, No. 12. pp. 1460-1466.
@article{fc1bd44921674834ba1f7f37313ebbc6,
title = "Autoimmune gastritis: Histology phenotype and OLGA staging",
abstract = "Background Among Western populations, the declining incidence of Helicobacter pylori infection coincides with a growing clinical impact of autoimmune gastritis. Aims To describe the histological phenotype of autoimmune gastritis, also to test the prognostic impact of OLGA staging in the autoimmune setting. Methods A single-institutional series (spanning the years 2003-2011) of 562 consecutive patients (M:F ratio: 1:3.7; mean age = 57.6 ± 14.4 years) with serologically confirmed autoimmune gastritis underwent histology review and OLGA staging. Results Helicobacter pylori infection was ascertained histologically in 44/562 cases (7.8{\%}). Forty six biopsy sets (8.2{\%}) featured OLGA stages III-IV; they included all four cases of incidental epithelial neoplasia (three intraepithelial and one invasive; three of these four cases had concomitant H. pylori infection). There were 230 (40.9{\%}) and 139 (24.7{\%}) cases, respectively, of linear and micro-nodular enterochromaffin-like cell hyperplasia; 19 (3.4{\%}) type I carcinoids were detected. The series included 116 patients who underwent repeated endoscopy/biopsy sampling (mean time elapsing between the two procedures = 54 months; range 24-108). Paired histology showed a significant (P = 0.009) trend towards a stage progression [the stage increased in 25/116 cases (22{\%}); it remained unchanged in 87/116 cases (75{\%})]. Conclusions In autoimmune gastritis, the cancer risk is restricted to high-risk gastritis stages (III-IV), and is associated mainly with concomitant H. pylori infection. OLGA staging consistently depicts the time-dependent organic progression of the autoimmune disease and provides key information for secondary gastric cancer prevention strategies.",
author = "M. Rugge and M. Fassan and M. Pizzi and V. Zorzetto and G. Maddalo and S. Realdon and {De Bernard}, M. and C. Betterle and R. Cappellesso and G. Pennelli and {De Boni}, M. and F. Farinati",
year = "2012",
month = "6",
doi = "10.1111/j.1365-2036.2012.05101.x",
language = "English",
volume = "35",
pages = "1460--1466",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "12",

}

TY - JOUR

T1 - Autoimmune gastritis

T2 - Histology phenotype and OLGA staging

AU - Rugge, M.

AU - Fassan, M.

AU - Pizzi, M.

AU - Zorzetto, V.

AU - Maddalo, G.

AU - Realdon, S.

AU - De Bernard, M.

AU - Betterle, C.

AU - Cappellesso, R.

AU - Pennelli, G.

AU - De Boni, M.

AU - Farinati, F.

PY - 2012/6

Y1 - 2012/6

N2 - Background Among Western populations, the declining incidence of Helicobacter pylori infection coincides with a growing clinical impact of autoimmune gastritis. Aims To describe the histological phenotype of autoimmune gastritis, also to test the prognostic impact of OLGA staging in the autoimmune setting. Methods A single-institutional series (spanning the years 2003-2011) of 562 consecutive patients (M:F ratio: 1:3.7; mean age = 57.6 ± 14.4 years) with serologically confirmed autoimmune gastritis underwent histology review and OLGA staging. Results Helicobacter pylori infection was ascertained histologically in 44/562 cases (7.8%). Forty six biopsy sets (8.2%) featured OLGA stages III-IV; they included all four cases of incidental epithelial neoplasia (three intraepithelial and one invasive; three of these four cases had concomitant H. pylori infection). There were 230 (40.9%) and 139 (24.7%) cases, respectively, of linear and micro-nodular enterochromaffin-like cell hyperplasia; 19 (3.4%) type I carcinoids were detected. The series included 116 patients who underwent repeated endoscopy/biopsy sampling (mean time elapsing between the two procedures = 54 months; range 24-108). Paired histology showed a significant (P = 0.009) trend towards a stage progression [the stage increased in 25/116 cases (22%); it remained unchanged in 87/116 cases (75%)]. Conclusions In autoimmune gastritis, the cancer risk is restricted to high-risk gastritis stages (III-IV), and is associated mainly with concomitant H. pylori infection. OLGA staging consistently depicts the time-dependent organic progression of the autoimmune disease and provides key information for secondary gastric cancer prevention strategies.

AB - Background Among Western populations, the declining incidence of Helicobacter pylori infection coincides with a growing clinical impact of autoimmune gastritis. Aims To describe the histological phenotype of autoimmune gastritis, also to test the prognostic impact of OLGA staging in the autoimmune setting. Methods A single-institutional series (spanning the years 2003-2011) of 562 consecutive patients (M:F ratio: 1:3.7; mean age = 57.6 ± 14.4 years) with serologically confirmed autoimmune gastritis underwent histology review and OLGA staging. Results Helicobacter pylori infection was ascertained histologically in 44/562 cases (7.8%). Forty six biopsy sets (8.2%) featured OLGA stages III-IV; they included all four cases of incidental epithelial neoplasia (three intraepithelial and one invasive; three of these four cases had concomitant H. pylori infection). There were 230 (40.9%) and 139 (24.7%) cases, respectively, of linear and micro-nodular enterochromaffin-like cell hyperplasia; 19 (3.4%) type I carcinoids were detected. The series included 116 patients who underwent repeated endoscopy/biopsy sampling (mean time elapsing between the two procedures = 54 months; range 24-108). Paired histology showed a significant (P = 0.009) trend towards a stage progression [the stage increased in 25/116 cases (22%); it remained unchanged in 87/116 cases (75%)]. Conclusions In autoimmune gastritis, the cancer risk is restricted to high-risk gastritis stages (III-IV), and is associated mainly with concomitant H. pylori infection. OLGA staging consistently depicts the time-dependent organic progression of the autoimmune disease and provides key information for secondary gastric cancer prevention strategies.

UR - http://www.scopus.com/inward/record.url?scp=84861194883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861194883&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2012.05101.x

DO - 10.1111/j.1365-2036.2012.05101.x

M3 - Article

C2 - 22519568

AN - SCOPUS:84861194883

VL - 35

SP - 1460

EP - 1466

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 12

ER -